Sitagliptin phosphate (formerly also known as MK-431; trade name Januvia; Xelevia; Janumet) monohydrate, is an oral bioavailable, triazolopyrazine-based, potent inhibitor of DPP-IV (dipeptidyl peptidase-4) with an IC50 of 19 nM in Caco-2 cell extracts. It is an antihyperglycemic and antidiabetic medication.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.